NVO

Novo Nordisk A/S

Add to Watchlist

Advanced Chart

49.995

-1.085(-2.124%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

50.470

Open

50.360

VWAP

50.27

Vol

2.60M

Mkt Cap

228.08B

Low

49.930

Amount

130.78M

EV/EBITDA(TTM)

9.59

Total Shares

4.45B

1.52T

EV/OCF(TTM)

12.53

P/S(TTM)

4.61

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

84.79B

+8.58%

84.85B

-0.97%

78.03B

+9.42%

Estimates Revision

The market is revising Downward the revenue expectations for Novo Nordisk A/S (NVO) for FY2025, with the revenue forecasts being adjusted by -5.42% over the past three months. During the same period, the stock price has changed by -26.20%.

Revenue Estimates for FY2025

Revise Downward

-5.42%

In Past 3 Month

Stock Price

Go Down

-26.20%

In Past 3 Month

6 Analyst Rating

39.61% Upside

Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 69.80 USD with a low forecast of 55.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

3 Hold

0 Sell

Moderate Buy

39.61% Upside

Current: 49.995

Low

55.00

Averages

69.80

High

90.00

39.61% Upside

Current: 49.995

Low

55.00

Averages

69.80

High

90.00

UBS

Buy -> Neutral

downgrade

2025-08-05

Reason

UBS

Price Target

2025-08-05

downgrade

Buy -> Neutral

Reason

UBS downgraded Novo Nordisk to Neutral from Buy with a price target of DKK 340, down from DKK 600. The firm sees "challenging times" for the company with its analysis indicating U.S. compounding of weight loss drugs is "here to stay." This leaves an uncertain outlook for Novo's Wegovy, the analyst tells investors in a research note.

Goldman Sachs

downgrade

2025-08-01

Reason

Goldman Sachs

Price Target

2025-08-01

downgrade

Reason

Goldman Sachs analysts removed Novo Nordisk from its European Conviction List as part of its monthly update.

Barclays

Overweight

Equal Weight

downgrade

2025-07-30

Reason

Barclays

Price Target

2025-07-30

downgrade

Overweight

Equal Weight

Reason

Barclays downgraded Novo Nordisk (NVO) to Equal Weight from Overweight with a price target of DKK 375, down from DKK 700. The company's profit warning may be a "kitchen sink," but semaglutide's return to volume growth lacks visibility, the analyst tells investors in a research note. Further, worth Novo's pipeline lagging behind Eli Lilly (LLY), Barclays does not see a catalyst to get investors to return the story.

Oddo BHF

Outperform

Neutral

downgrade

DKK 465

2025-07-30

Reason

Oddo BHF

Price Target

DKK 465

2025-07-30

downgrade

Outperform

Neutral

Reason

Oddo BHF downgraded Novo Nordisk to Neutral from Outperform with a DKK 465 price target.

BofA

Buy -> Neutral

downgrade

2025-07-30

Reason

BofA

Price Target

2025-07-30

downgrade

Buy -> Neutral

Reason

BofA downgraded Novo Nordisk to Neutral from Buy with a price target of DKK 375, down from DKK 550. The firm is lowering its Wegovy estimates for 2026/27 by about 20% with unclear timeline for resolution of compounding, which the company cited as the main headwind in its guidance cut, and lowers its 2025 EPS forecast by about 5%, its 2026 view by about 12% and outer years by a mid-high teens percentage.

JPMorgan

Overweight -> NULL

downgrade

2025-07-30

Reason

JPMorgan

Price Target

2025-07-30

downgrade

Overweight -> NULL

Reason

JPMorgan lowered the firm's price target on Novo Nordisk to DKK 500 from DKK 650 and keeps an Overweight rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Novo Nordisk A/S (NVO.N) is 11.96, compared to its 5-year average forward P/E of 28.38. For a more detailed relative valuation and DCF analysis to assess Novo Nordisk A/S 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

28.38

Current PE

11.96

Overvalued PE

34.24

Undervalued PE

22.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

20.24

Current EV/EBITDA

9.14

Overvalued EV/EBITDA

24.33

Undervalued EV/EBITDA

16.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

9.70

Current PS

4.25

Overvalued PS

11.79

Undervalued PS

7.61

Financials

Annual

Quarterly

FY2025Q2

YoY :

+18.85%

11.67B

Total Revenue

FY2025Q2

YoY :

+13.40%

5.18B

Operating Profit

FY2025Q2

YoY :

+39.12%

4.03B

Net Income after Tax

FY2025Q2

YoY :

+40.00%

0.91

EPS - Diluted

FY2025Q2

YoY :

-30.78%

3.72B

Free Cash Flow

FY2025Q2

YoY :

-1.90%

83.29

Gross Profit Margin - %

FY2025Q2

YoY :

-22.78%

19.76

FCF Margin - %

FY2025Q2

YoY :

+17.04%

34.48

Net Margin - %

FY2025Q2

YoY :

-21.04%

51.38

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 112.57% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

6.7M

Volume

6-9

Months

9.8M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.8M

Volume

Months

6-9

1.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

24.0K

USD

6-9

Months

0.0

USD

0-12

Months

83.0K

USD

Bought

0-3

0.0

USD

Months

3-6

40.5K

USD

Months

6-9

0.0

USD

Months

0-12

32.5K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

NVO News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

12:40:05

Mixed options sentiment in Novo Nordisk with shares up 4.87%

2025-08-07 (ET)

2025-08-07

15:53:34

Moderately bullish activity in Novo Nordisk with shares up 7.19%

2025-08-07

13:09:37

Video: Why Eli Lilly Is Underperforming Today

News

7.0

00:30 AMGlobenewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

6.5

08-10TipRanks

‘Time to Double Down,’ Says Top Investor About Novo Nordisk Stock

7.0

08-10Globenewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO